Barbara L. McAneny, MD, FASCO, MACP, has been elected president-elect of the American Medical Association. Following a year-long term as president-elect, McAneny will assume the role of AMA president in June 2018.
Barbara L. McAneny, MD, FASCO, MACP
Barbara L. McAneny, MD, FASCO, MACP
Barbara L. McAneny, MD, FASCO, MACP, has been elected president-elect of the American Medical Association (AMA). Following a year-long term as president-elect, McAneny will assume the role of AMA president in June 2018. She was elected to the position by her fellow physicians during the Annual Meeting of the AMA.
“It is a deep honor and privilege to be elected a leader of an organization that is committed to serving as a strong physician voice and a dedicated patient advocate,” McAneny said. “The AMA will play a pivotal role in the changing health care environment as our nation confronts pressing health care issues. With vision and perseverance, I look forward to creating a brighter future for patients and the medical profession.”
McAneny is the co-founder and CEO of New Mexico Oncology Hematology Consultants. Additionally, she built and manages the New Mexico Cancer Center, which provides comprehensive outpatient medical and radiation oncology care and imaging.
McAneny previously served on the board of the American Society of Clinical Oncology (ASCO) and was the delegate to the AMA from ASCO. She became an AMA board member in 2010, serving as board chair from 2015 to 2016.
She has held many leadership roles in medicine, including serving as president of the New Mexico Medical Society, the Greater Albuquerque Medical Association, and the New Mexico Chapter of the American College of Physicians. She served as chair of the AMA Council of Medical Service from 2009 to 2010.
“Today, the delegates of the American Medical Association (AMA) voted for Barbara McAneny, MD, FASCO, MACP, as the organization’s president-elect, making her the first oncologist elected to serve in this important leadership position,” ASCO President Bruce E. Johnson, MD, FASCO, said in a statement.
Post Hoc and Real-World Analyses Explore Benefit of Lenvatinib in DTC
December 5th 2024During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer in the second article of a 2-part series.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen